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journal homepage: www.ejves.comEditorialEndovascular Aortic Aneurysm Repair – Still a Failed Experiment?Endovascular aneurysm repair [EVR] has been described as
unethical, ﬁnancially unviable and a ‘failed experiment’.1 Although
the uptake of EVR has ﬂourished with a robust evidence base, there
remains concern regarding long-termviability, fed by the long-term
outcome data from the EVAR-1 trial.2 The authors reiterated the
early survival advantage following EVR compared to open surgery
[OR] (adjusted odds ratio for EVR vs. OR, 0.39; 95% conﬁdence
interval [CI], 0.18 to 0.87; P ¼ 0.02) but highlighted the 8-year
follow-up data as demonstrating that EVR is associated with
increased rates of graft-related complications, re-interventions and
cost despite similar aneurysm-related mortality (adjusted hazard
ratio, 0.92; 95% CI, 0.57 to 1.49; P ¼ 0.73). These long-term results
of EVAR-1 have been lauded by endovascular sceptics as a failure
of the technology. Furthermore, additional subgroup analysis from
EVAR-1 has described signiﬁcant numbers of aortic ruptures with
associated mortality.3 It would appear, from EVAR-1 trial data, that
the catch up in aneurysm-related mortality in the EVR group is due
to the development of endograft-related complications and rupture.
It remains imperative that endovascular techniques should be
robustly evaluated, but the question as to whether open surgery or
endovascular repairoffers the “best approach” is toosimplistic, espe-
cially for patients deemed unﬁt for OR.
Theﬁndings reported inEVAR-1 raisequestions regarding the rele-
vance of historical clinical trials in guidingmodern day vascular prac-
tice. Wewould argue that it is time to move on from the EVAR-1 trial
and the interpretation of the long-term results in favour of OR.While
representing thebestclinical trialof its kind, it is nowahistorical study
which was never powered to investigate the longer term outcomes.
Vascular clinical practice has changed dramatically, as have our
understanding of the role of surveillance and re-intervention.
Firstly, the provision of service has changed. Vascular units have
reconﬁgured with a drive towards centralised arterial surgery, the
highest volume centres producing the best results despite more
complex case mix. Units recruiting patients to EVAR-1 qualiﬁed
having performed as few as 20 cases. The learning curve is recog-
nized as much longer. To be considered ‘well-trained’ a unit should
have performed 55–60 cases.4 It could be argued that the complex-
ities of care in the follow-up period are not truly appreciated until
several hundred patients have been treated.
Secondly, vascular surgeons have clearer understanding of
endovascular techniques with enhanced quality control, surveil-
lance regimens and appreciation for when and how to intervene.
EVAR-1 reported a 23.1% re-intervention rate. Units with large
EVR experience have demonstrated this does not translate to
current practice reporting re-intervention rates as low as 7.4%.5
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means every effort is made to ensure no patient leave the operating
suitewith a type I or III endoleak. At least 81.5% of the graft ruptures
that occurred in EVAR-1 and subsequent aneurysm-related
mortality could have been avoided with current practice, as
demonstrated in our own units unpublished data of 0.897 aortic
deaths per 100 patient years following 478 cases.
Finally, device technology has evolved rendering the EVAR-1
devices outmoded and data from long-term follow-up inconse-
quential. Improved neck ﬁxation and iliac limb conformity have
reduced type I endoleaks and graft migration. Lower-proﬁle devices
with lubricious delivery systems have extended the eligibility to
patients with difﬁcult access. In EVAR-1 morphological eligibility
was 43%. With current device ‘instructions for use’, it is 80%.
Current peri-operative EVR mortality in these more challenging
populations remain vastly superior to OR [1.2% vs. 4.8%, P< 0.001].6
The shift towards an endovascular-dominated practice is multi-
factorial, combining clinical factors, scientiﬁc progress and patient
choice. When provided with the evidence, patients prefer EVR
because of the over-riding beneﬁt in early survival and reduced
risk of organ dysfunction.7 Patients are willing to travel to central-
ised units, to receive EVR with the added incentives of survival and
prompt restoration of quality of life.8 Sceptics often fall back on
the argument of cost yet EVAR-1 presents an unfair and inaccurate
comparison between EVR and OR. There is no record of laparotomy-
related complications and associated costs. Surveillance post EVR
has been rationalised to duplex and may yet become more
patient-speciﬁc, reducing this burden further.
EVR is certainly not a failed experiment; and represents the
principle driver for reduced AAA mortality. Patients will vote with
their feet and seek out EVR rather than expose themselves to the
unnecessary peri-operative risk associated with OR. The tables
have surely turned. Given the evidence, considering the risks, if
morphologically suitable the authors could not consent to OR and
are astonished that so many patients still do.References
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